OBJECTIVE: The objective of the study was to identify prognostic and environmental factors associated with vulvar carcinoma in young women. STUDY DESIGN: This study was a review of patients younger than 45 years who were diagnosed with vulvar squamous cell carcinoma between 1994 and 2006. RESULTS: Fifty-six patients were identified. Median age was 38 years and median follow-up was 25.3 months. Fifty-eight percent of patients presented with stage I disease; 77% smoked tobacco. Of patients with advanced disease, 53.3% were smokers, 40% had human papillomavirus (HPV) exposure, 46.7% had a history of vulvar intraepithelial neoplasia (VIN), and 6.7% were immunocompromised. Symptoms were present for more than 12 months in 47%, but symptom duration did not correlate with stage (P = .42) or positive lymph nodes (P = .28). Disease recurred in 10.7% and 5.4% died of disease. CONCLUSION: Young women with vulvar cancer tend to have early-stage disease, smoke, have a history of HPV, and have VIN. Many of the factors that place these patients at continuous risk are modifiable.
OBJECTIVE: The objective of the study was to identify prognostic and environmental factors associated with vulvar carcinoma in young women. STUDY DESIGN: This study was a review of patients younger than 45 years who were diagnosed with vulvar squamous cell carcinoma between 1994 and 2006. RESULTS: Fifty-six patients were identified. Median age was 38 years and median follow-up was 25.3 months. Fifty-eight percent of patients presented with stage I disease; 77% smoked tobacco. Of patients with advanced disease, 53.3% were smokers, 40% had human papillomavirus (HPV) exposure, 46.7% had a history of vulvar intraepithelial neoplasia (VIN), and 6.7% were immunocompromised. Symptoms were present for more than 12 months in 47%, but symptom duration did not correlate with stage (P = .42) or positive lymph nodes (P = .28). Disease recurred in 10.7% and 5.4% died of disease. CONCLUSION: Young women with vulvar cancer tend to have early-stage disease, smoke, have a history of HPV, and have VIN. Many of the factors that place these patients at continuous risk are modifiable.
Authors: André Mourão Lavorato-Rocha; Iara Sant'ana Rodrigues; Beatriz de Melo Maia; Mônica Maria Ágata Stiepcich; Glauco Baiocchi; Kátia Cândido Carvalho; Fernando Augusto Soares; José Vassallo; Rafael Malagoli Rocha Journal: Tumour Biol Date: 2013-07-06
Authors: Ramakhosana S Hlapane; Thandekile L Khumalo; Bongumusa S Makhathini; Jagidesa Moodley Journal: South Afr J HIV Med Date: 2021-09-08 Impact factor: 2.744
Authors: Beatriz de Melo Maia; André Mourão Lavorato-Rocha; Iara Sant'ana Rodrigues; Glauco Baiocchi; Flávia Munhoz Cestari; Monica Maria Stiepcich; Ludmila Thomé Domingues Chinen; Kátia C Carvalho; Fernando Augusto Soares; Rafael Malagoli Rocha Journal: J Transl Med Date: 2012-07-28 Impact factor: 5.531
Authors: I S Rodrigues; A M Lavorato-Rocha; B de M Maia; M M A Stiepcich; F M de Carvalho; G Baiocchi; F A Soares; R M Rocha Journal: Br J Cancer Date: 2013-06-18 Impact factor: 7.640
Authors: Maria das Graças de Fátima Cavalcanti Castor; Leuridan Cavalcante Torres; Roberto José Vieira de Mello; Rodrigo de Andrade Natal; José Vassallo Journal: Sci Rep Date: 2020-03-27 Impact factor: 4.379